CSDE1 Intracellular Distribution as a Biomarker of Melanoma Prognosis
Indacochea, Alberto (Centre for Genomic Regulation (CRG). The Barcelona Institute of Science and Technology)
Guitart, Tanit (Centre for Genomic Regulation (CRG). The Barcelona Institute of Science and Technology)
Boada, Aram (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Peg, Vicente (Hospital Universitari Vall d'Hebron)
Quer, Ariadna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Laayouni, Hafid (Barcelona Beta Brain Research Center. Pasqual Maragall Foundation)
Condal, Laura (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Espinosa, Pablo (Centre for Genomic Regulation (CRG). The Barcelona Institute of Science and Technology)
Manzano, José Luís (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Gebauer, Fátima (Universitat Pompeu Fabra. Departament de Medicina i Ciències de la Vida)

Fecha:	2024
Resumen:	RNA-binding proteins are emerging as critical modulators of oncogenic cell transformation, malignancy and therapy resistance. We have previously found that the RNA-binding protein Cold Shock Domain containing protein E1 (CSDE1) promotes invasion and metastasis of melanoma, the deadliest form of skin cancer and also a highly heterogeneous disease in need of predictive biomarkers and druggable targets. Here, we design a monoclonal antibody useful for IHC in the clinical setting and use it to evaluate the prognosis potential of CSDE1 in an exploratory cohort of 149 whole tissue sections including benign nevi and primary tumors and metastasis from melanoma patients. Contrary to expectations for an oncoprotein, we observed a global decrease in CSDE1 levels with increasing malignancy. However, the CSDE1 cytoplasmic/nuclear ratio exhibited a positive correlation with adverse clinical features of primary tumors and emerged as a robust indicator of progression free survival in cutaneous melanoma, highlighting the potential of CSDE1 as a biomarker of prognosis. Our findings provide a novel feature for prognosis assessment and highlight the intricacies of RNA-binding protein dynamics in cancer progression.
Ayudas:	Agencia Estatal de Investigación PGC2018-099697-B-I00 Agencia Estatal de Investigación PID2021-127948NB-I00 Agència de Gestió d'Ajuts Universitaris i de Recerca 2021/SGR-01215 "la Caixa" Foundation 100010434
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	CSDE1 ; RNA-binding protein ; Biomarker ; Cytoplasmic-nuclear ratio ; Melanoma ; Prognosis
Publicado en:	International journal of molecular sciences, Vol. 25 Núm. 4 (february 2024) , p. 2319, ISSN 1422-0067

DOI: 10.3390/ijms25042319
PMID: 38396995

13 p, 2.0 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Artículos > Artículos de investigación
Artículos > Artículos publicados